Quarterly Updates9 Feb 2026, 05:51 pm
Neuland Laboratories: Revenues Align with Outlook, Subdued EBITDA Margins
AI Summary
Neuland Laboratories Limited, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services, announced financial results for the nine months ended Dec 31, 2025. The revenues are in line with the outlook, but the product mix and increased operating expenses have led to subdued EBITDA margins. The company is seeing increasing interest from a wider range of customers, which is driving their investments. The financial summary for Q3FY26 shows a YoY increase in total income by 114% and a QoQ increase by 132%. However, EBITDA and PBT margins have seen a decrease.
Key Highlights
- Revenues are in line with the outlook for the year
- Subdued EBITDA margins due to product mix and increased operating expenses
- Increasing interest from a wider range of customers
- Investments leading to more engagements with existing and new customers
- YoY total income increase by 114% and QoQ increase by 132%